Normunity has launched with 1) a powerful premise to reach novel I-O targets to free normal immunity, 2) a unique R&D model working with the Lieping Chen lab and 3) strong momentum to advance life-changing medicines for patients. #NormunityAgainstCancer https://t.co/six3jYfq1b

Congratulations to the Normunity team for today’s exciting launch. Looking forward to great things and #ImmuneNormalizers to come. #NormunityAgainstCancer https://t.co/six3jYfq1b

Normunity’s pipeline of novel cancer immunotherapies is drawn from the ongoing & interactive academic-biotech research leveraging proprietary discovery platforms from the lab of Dr. Lieping Chen at Yale School of Medicine. #NormunityAgainstCancer https://t.co/six3jYxzfj

We’re thrilled to unveil Normunity to the biotech world. @bostonglobe @RLCscienceboss explores our revolutionary approach to novel cancer immunotherapies that free the normal immune system to fight cancer. #NormunityAgainstCancer https://t.co/acUe9RCzLU

Normunity announces $65 million Series A to expand the frontier of precision immuno-oncology with immune normalizer therapies. Our medicines target unprecedented mechanisms that free the body’s normal immunity against cancer. #NormunityAgainstCancer https://t.co/KTKa2lhlkz